Actualizacion sobre sobre diagnóstico, tratamiento y prevención de Botulismo.
Barra lateral del artículo
Contenido principal del artículo
Resumen
El botulismo es una enfermedad neuroparalítica, descendente y simétrica. Rara y potencialmente mortal, causada por neurotoxinas producidas por el Clostridium botulinum e infrecuentemente por otros Clostridium. La toxina bloquea de forma irreversible la liberación de acetilcolina en la unión neuromuscular. La vigilancia epidemiológica es fundamental para implementar medidas de prevención y control, así como para el tratamiento precoz de los casos sospechosos, la identificación del agente y la planificación de las intervenciones.
Expertos de la Sociedad Argentina de Terapia Intensiva (SATI) acordaron actualizar sobre diagnóstico, tratamiento y prevención de botulismo. Se analizó la bibliografía publicada en los últimos años, especialmente aquella de gran relevancia en el tema. El objetivo es trasmitir herramientas básicas de optimización en el diagnóstico según criterios clínicos y del laboratorio especializado, orientación en el tratamiento, y promover un precoz reconocimiento.
Detalles del artículo
La revista no retiene los derechos de reproducción (copyright) por lo que los autores pueden volver a publicar sus trabajos con la sola mención a la fuente original de publicación.
Citas
Peck MW. Biology and genomic analysis of Clostridium botulinum. Adv Microb Physiol. 2009;55:183–265.
Dhaked RK, Singh MK, Singh P, et al. Botulinum toxin: bioweapon & magic drug. Indian J Med Res. 2010;132:489–503.
International Commission on Microbiological Specifications for Foods. Clostridium botulinum. In: Micro-organisms in foods 6: microbial ecology and food commodities. New York (NY): Kluwer Academic; 2005. p. 277–325
Collins MD, East AK . Phylogeny and taxonomy of the food-borne pathogen Clostridium botulinum and its neurotoxins. J Appl Microbiol. 1998;84:5-17
Aureli P , Fenicia L , Pasolini B , Gianfranceschi M , McCroskey LM , Hatheway CL . Two cases of type E infant botulism caused by neurotoxigenic Clostridium butyricum in Italy. J Infect Dis. 1986;154:207-211
Giménez DF , Ciccarelli AS . Another type of Clostridium botulinum. Zentralbl Bakteriol Orig. 1970;215:221-224.
Hall JD , McCroskey LM , Pincomb BJ , Hatheway CL . Isolation of an organism resembling Clostridium barati which produces type F botulinal toxin from an infant with botulism. J Clin Microbiol. 1985;21:654-655.
Hill KK, Xie G, Foley BT, Smith TJ, Munk AC, Bruce D, Smith LA, Brettin TS, Detter JC. Recombination and insertion events involving the botulinum neurotoxin complex genes in Clostridium botulinum types A, B, E and F and Clostridium butyricum type E strains. BMC Biol. 2009;7:66.
Halpin JL, Hill K, Johnson SL, Bruce DC, Shirey TB, Dykes JK, Lúquez C. Finished Whole-Genome Sequence of Clostridium argentinense Producing BotulinumNeurotoxin Type G. Genome Announc. 2017;5(21)
Hill KK, Smith TJ. Genetic diversity within Clostridium botulinum serotypes, botulinum neurotoxin gene clusters and toxin subtypes. Curr Top Microbiol Immunol. 2013;364:1–20.
MarÃa A. Carrillo-Márquez. Botulism. Pediatrics in Review. Mayo 2016;37:183-192
Joseph Jankovic. Botulinum Toxin: State of the Art. Movement Disorders. 2017;32:1131-1138
Centers for Disease Control and Prevention. National botulism surveillance. cdc.gov/ botulism/surveillance.html. Updated April 18, 2017.
Koepke R, Sobel J, Arnon SS. Global occurrence of infant botulism, 1976–2006. Pediatrics 2008; 122(1):e73–e82.
World Health Organization. The expanded programme on immunization. who.int/immunization/programmes_systems/supply_chain/benefits_of_immunization/en/. Updated December 1, 2013.
Rosow LK, Strober JB. Infant botulism: review and clinical update. Pediatr Neurol 2015;52:487–492.
Sobel J, Tucker N, Sulka A, et al. Foodborne botulism in the United States, 1990–2000. Emerg Infect Dis 2004;10:1606–1611.
Maselli RA, Ellis W, Mandler RN, et al. Cluster of wound botulism in California: clinical, electrophysiologic, and pathologic study. Muscle Nerve 1997;20:1284–1295.
David WS, Temin ES, Kraeft JJ, Hooper DC. Case 3-2015: a woman with abdominal pain, dyspnea, and diplopia. N Engl J Med 2015;372:364–372.
Gupta A, Sumner CJ, Castor M, et al. Adult botulism type F in the United States, 1981–2002. Neurology 2005;65:1694–1700.
Chertow DS, Tan ET, Maslanka SE, et al. Botulism in 4 adults following cosmetic injections with an unlicensed, highly concentrated botulinum preparation. JAMA 2006;296:2476–2479
Gottlieb SL, Kretsinger K, Tarkhashvili N, et al. Long-term outcomes of 217 botulism cases in the Republic of Georgia. Clin Infect Dis 2007;45:174–180.
Kimberlin DW, Brady MT, Jackson MA, Long SS; Committee on Infectious Diseases; American Academy of Pediatrics. Botulism. In: Red book: 2015 report of the Committee on Infectious Diseases Itasca, IL: American Academy of Pediatrics, 2015.
Kongsaengdao S, Samintarapanya K, Rusmeechan S, et al. Electrophysiological diagnosis and patterns of response to treatment of botulism with neuromuscular respiratory failure. Muscle Nerve 2009;40:271–278.
Arnon SS, Schechter R, Maslanka SE, et al. Human botulism immune globulin for the treatment of infant botulism. N Engl J Med 2006;354:462–471.
Botulism antitoxin heptavalent prescribing information. Cangene Corporation. BAT (botulism antitoxin heptavalent [A, B, C, D, E, F, G] - [equine]) prescribingin formation.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ ApprovedProducts/LicensedProductsBLAs/ FractionatedPlasmaProducts/UCM345147.pdf. Updated March 2017